"Prevnar is a fantastic vaccine that is taking care of the top seven strains of pneumococcal disease, but after you've knocked down the other strains, of course others will become more prominent," Pichichero explained.
Dr. Peter Paradiso is vice president of scientific affairs for Wyeth Pharmaceuticals. He said, "When we developed Prevnar, we had hoped that the response to serotype 19F would provide some cross-protection against 19A." When it became clear that there was no cross-protection, and other strains needed to be addressed, Wyeth added six more strains to the next generation vaccine. The company plans to begin the regulatory filings needed for FDA approval sometime in 2009, after the phase III trials are completed, he said.
In the meantime, Pichichero said physicians need to do more ear tap procedures to identify which bacteria are causing antibiotic-resistant ear infections. Doing so, he said, would help avoid the unnecessary use of antibiotics and allow for a more targeted approach to treating ear infections.
From 2003 until 2006, Pichichero and his colleagues saw just over 1,800 youngsters with ear infections, according to the study. Of those children, 212 had ear taps, known as tympanocentesis, a procedure that draws fluid out from behind the ear drum. Much like when a tooth cavity is filled, children are given local anesthetic to make the procedure pain-free.
Using this procedure, the doctors found that 59 of the ear infections were caused by S. pneumoniae. One particular strain of the bacterium -- serotype 19A -- had developed a new genotype that was resistant to all of the antibiotics approved for use in children. Pichichero and his colleague, Dr. Janet Casey,
'/>"/>
| Copyright©2007 ScoutNews,LLC. All rights reserved |